Home LiteratureArticle Details
PMID: 12795527 Published · ppublish English Journal Article Review

Reversal of tumor-induced immunosuppression by TGF-beta inhibitors.

Investigational new drugs ·Vol. 21 ·No. 1 ·2003-02-00 ·Pages 21-32

Wojtowicz-Praga S

Abstract

The immune system is responsible for the early detection and destruction of newly transformed malignant cells. Some transformed cells become immunologically invisible by passive avoidance of immune surveillance (i.e., when tumor cells are immunologically indistinguishable from normal cells). Other transformed cells actively secrete cytokines that effectively blind the immune system to the presence of abnormal antigens on the tumor cell surface. Transforming growth factor-beta ("TGF-beta"), which is expressed by a majority of malignant tumors, is the most potent immunosuppressor and therefore, the most likely cytokine to be responsible for the latter phenomenon. In addition to playing a key role in tumor-induced immunosuppression, TGF-beta stimulates angiogenesis. Interestingly, tumor cells eventually become refractory to TGF-beta-mediated growth arrest, either due to loss of TGF-beta receptors or due to dysregulation in TGF-beta signaling pathways. Neutralization of TGF-beta or inhibition of its production is an effective method of cancer treatment in variety of animal models. Several agents targeting TGF-beta are in the early stages of development and include anti-TGF-beta antibodies, small molecule inhibitors of TGF-beta, Smad inhibitors and antisense gene therapy. Since tumors may express more than one isoform of TGF-beta, these new drugs should target all three TGF-beta isoforms produced by human tumors. The effects of therapies targeting TGF-beta are likely to be synergistic with cytotoxic chemotherapy and immunotherapy. Reversal of TGF-beta-induced immunosuppression is a new and promising approach to cancer therapy, with potential applications in other diseases such as AIDS.

MeSH Terms
Animals Antibodies, Monoclonal/therapeutic use DNA-Binding Proteins/antagonists & inhibitors Humans Immune Tolerance/drug effects Immunotherapy, Active Neoplasm Metastasis Neoplasms/immunology,pathology,therapy Smad Proteins Trans-Activators/antagonists & inhibitors Transforming Growth Factor beta/antagonists & inhibitors,immunology
Chemicals
Antibodies, Monoclonal DNA-Binding Proteins Smad Proteins Trans-Activators Transforming Growth Factor beta
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Wojtowicz-Praga Slawomir
[email protected]
References (117)
117 references, click to expand
  1. Serum transforming growth factor-beta 1 is related to the degree of immunoparesis in patients with multiple myeloma.
    Med Oncol. 1998 Jul;15(2):124-8 PMID: 9789221
  2. Transforming growth factor beta 1-hyaluronic acid interaction.
    Cell Tissue Res. 1995 Aug;281(2):317-24 PMID: 7648625
  3. Identification of a transforming growth factor beta-1 activator derived from a human gastric cancer cell line.
    Br J Cancer. 1995 Sep;72 (3):676-82 PMID: 7669580
  4. Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor beta receptor therapy.
    Cancer Res. 1999 Mar 15;59(6):1273-7 PMID: 10096559
  5. Altered expression of transforming growth factor-beta ligands and receptors in primary and recurrent ovarian carcinoma.
    Cancer. 1999 Feb 1;85(3):658-68 PMID: 10091739
  6. Expression of transforming growth factor-beta 1 in prostate cancer.
    Endocrinology. 1994 Nov;135(5):2240-7 PMID: 7956947
  7. Tranilast inhibits the proliferation, chemotaxis and tube formation of human microvascular endothelial cells in vitro and angiogenesis in vivo.
    Br J Pharmacol. 1997 Nov;122(6):1061-6 PMID: 9401770
  8. TGF-beta-based immunotherapy for cancer: breaching the tumor firewall.
    Prostate. 2000 Oct 1;45(2):167-72 PMID: 11027416
  9. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta.
    Biochem J. 1994 Sep 1;302 ( Pt 2):527-34 PMID: 8093006
  10. Reversal of tumor-induced immunosuppression: a new approach to cancer therapy.
    J Immunother. 1997 May;20(3):165-77 PMID: 9181454
  11. Transforming growth factor beta signaling through Smad1 in human breast cancer cells.
    Cancer Res. 1998 Oct 15;58(20):4752-7 PMID: 9788633
  12. Multiple forms of TGF-beta 1 in breast tissues: a biologically active form of the small latent complex of TGF-beta 1.
    Eur J Cancer. 1996 Aug;32A(9):1566-73 PMID: 8911119
  13. Transforming growth factor beta1, urokinase-type plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in head and neck squamous carcinoma and normal adjacent mucosa.
    Head Neck. 2001 Sep;23(9):725-32 PMID: 11505481
  14. The relevance of transforming growth factor beta 1 in pulmonary injury after radiation therapy.
    Lung Cancer. 1998 Feb;19(2):109-20 PMID: 9567247
  15. Tranilast Kissei Pharmaceutical.
    IDrugs. 1998 May;1(1):141-6 PMID: 18465519
  16. Autocrine stimulatory mechanism by transforming growth factor beta in human hepatocellular carcinoma.
    Cancer Res. 2000 Mar 1;60(5):1394-402 PMID: 10728705
  17. Transforming growth factor-beta in in vivo resistance.
    Cancer Chemother Pharmacol. 1996;37(6):601-9 PMID: 8612316
  18. Smad6 inhibits signalling by the TGF-beta superfamily.
    Nature. 1997 Oct 9;389(6651):622-6 PMID: 9335505
  19. Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2.
    J Immunother. 1998 Mar;21(2):85-94 PMID: 9551359
  20. Immunological measurement of transforming growth factor-beta 1 (TGF-beta1) in blood; assay development and comparison.
    Clin Chem. 1997 Oct;43(10):1965-74 PMID: 9342020
  21. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells.
    Nat Med. 2001 Oct;7(10):1118-22 PMID: 11590434
  22. TGF-beta signalling from cell membrane to nucleus through SMAD proteins.
    Nature. 1997 Dec 4;390(6659):465-71 PMID: 9393997
  23. Latency-associated peptide of transforming growth factor beta enhances mycobacteriocidal immunity in the lung during Mycobacterium bovis BCG infection in C57BL/6 mice.
    Infect Immun. 2000 Nov;68(11):6505-8 PMID: 11035768
  24. Inhibition of tumor necrosis factor-alpha and -beta secretion by lymphokine activated killer cells by transforming growth factor-beta.
    Jpn J Cancer Res. 1994 Sep;85(9):952-7 PMID: 7961125
  25. The role of transforming growth factor beta in the generation of suppression: an interaction between CD8+ T and NK cells.
    J Exp Med. 1994 Nov 1;180(5):1937-42 PMID: 7964469
  26. The tumor suppressor Smad4/DPC 4 as a central mediator of Smad function.
    Curr Biol. 1997 Apr 1;7(4):270-6 PMID: 9094310
  27. Latent transforming growth factor beta1 activation in situ: quantitative and functional evidence after low-dose gamma-irradiation.
    FASEB J. 1997 Oct;11(12):991-1002 PMID: 9337152
  28. Smads are the central component in transforming growth factor-beta signaling.
    Pharmacol Ther. 1998 Apr;78(1):47-52 PMID: 9593329
  29. Combination of transforming growth factor beta antisense and interleukin-2 gene therapy in the murine ovarian teratoma model.
    Gynecol Oncol. 1998 Nov;71(2):204-10 PMID: 9826461
  30. Expression of transforming growth factor beta (TGF beta) receptors and expression of TGF beta 1, TGF beta 2 and TGF beta 3 in human small cell lung cancer cell lines.
    Br J Cancer. 1993 May;67(5):1015-21 PMID: 8388229
  31. High levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer.
    Cancer Epidemiol Biomarkers Prev. 1995 Jul-Aug;4(5):549-54 PMID: 7549813
  32. Transforming growth factor beta 1 as a prognostic factor in pulmonary adenocarcinoma.
    J Clin Pathol. 1994 Dec;47(12):1098-100 PMID: 7876382
  33. Regulation of adhesion and adhesion molecules in endothelium by transforming growth factor-beta.
    Curr Top Microbiol Immunol. 1993;184:187-99 PMID: 7508840
  34. Regulation of osteogenesis by fetuin.
    J Biol Chem. 1999 Oct 1;274(40):28514-20 PMID: 10497215
  35. Constitutive secretion of bioactive transforming growth factor beta 1 by small cell lung cancer cell lines.
    Eur J Cancer. 1994;30A(14):2125-9 PMID: 7857713
  36. Association of transforming growth factor-beta 1 with prostate cancer: an immunohistochemical study.
    Hum Pathol. 1993 Jan;24(1):4-9 PMID: 7678092
  37. Oncogenic ras represses transforming growth factor-beta /Smad signaling by degrading tumor suppressor Smad4.
    J Biol Chem. 2001 Aug 3;276(31):29531-7 PMID: 11371552
  38. Expression of growth factors and their receptors in human esophageal carcinomas: regulation of expression by epidermal growth factor and transforming growth factor alpha.
    J Cancer Res Clin Oncol. 1993;119(7):401-7 PMID: 8491760
  39. The complete cDNA and amino acid sequence of bovine fetuin. Its homology with alpha 2HS glycoprotein and relation to other members of the cystatin superfamily.
    J Biol Chem. 1990 Mar 15;265(8):4354-7 PMID: 1689725
  40. Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: mapping of ligand binding and GAG attachment sites.
    J Cell Biol. 1994 Feb;124(4):557-68 PMID: 8106553
  41. Transforming growth factor-beta signaling in epithelial cells.
    Pharmacol Ther. 1997;75(1):21-41 PMID: 9364579
  42. Tranilast (N-(3,4-dimethoxycinnamoyl) anthranilic acid) down-regulates the growth of scirrhous gastric cancer.
    Anticancer Res. 1997 Mar-Apr;17(2A):895-900 PMID: 9137424
  43. Transforming growth factor beta and cancer.
    Cancer Treat Rev. 1995 Jul;21(4):367-403 PMID: 7585661
  44. Dual role for the latent transforming growth factor-beta binding protein in storage of latent TGF-beta in the extracellular matrix and as a structural matrix protein.
    J Cell Biol. 1995 Oct;131(2):539-49 PMID: 7593177
  45. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival.
    Gastroenterology. 1993 Dec;105(6):1846-56 PMID: 8253361
  46. Transforming growth factor beta from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T lymphocytes.
    J Leukoc Biol. 1999 Dec;66(6):981-8 PMID: 10614781
  47. TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4.
    EMBO J. 1997 Sep 1;16(17):5353-62 PMID: 9311995
  48. Expression of transforming growth factor-beta1 and transforming growth factor-beta Type-II receptor mRNA in papillary thyroid carcinoma.
    Horm Metab Res. 1998 Oct;30(10):624-8 PMID: 9851670
  49. Inhibition of proliferation of MCF-7 breast cancer cells by a blocker of Ca(2+)-permeable channel.
    Cell Calcium. 1997 Aug;22(2):75-82 PMID: 9292225
  50. SMADs: mediators and regulators of TGF-beta signaling.
    Curr Opin Genet Dev. 1998 Feb;8(1):103-11 PMID: 9529613
  51. Suppression of IL-2-induced T cell proliferation and phosphorylation of STAT3 and STAT5 by tumor-derived TGF beta is reversed by IL-15.
    J Immunol. 2001 Jul 1;167(1):553-61 PMID: 11418694
  52. Transforming growth factor-beta: latent forms, binding proteins and receptors.
    Growth Factors. 1993;8(1):11-22 PMID: 8383513
  53. The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer.
    Oncogene. 1999 Sep 23;18(39):5363-72 PMID: 10498890
  54. Cytokine profile of cervical cancer cells.
    Gynecol Oncol. 2001 Nov;83(2):235-43 PMID: 11606077
  55. Distinct roles of the intracellular domains of transforming growth factor-beta type I and type II receptors in signal transduction.
    J Biol Chem. 1994 Dec 9;269(49):30753-6 PMID: 7983000
  56. Dose-dependent induction of transforming growth factor beta (TGF-beta) in the lung tissue of fibrosis-prone mice after thoracic irradiation.
    Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):1033-42 PMID: 10863076
  57. Transforming growth factor-beta and response to anticancer therapies in human liver and gastric tumors in vitro and in vivo.
    Int J Oncol. 2000 Mar;16(3):599-610 PMID: 10675495
  58. Bone matrix decorin binds transforming growth factor-beta and enhances its bioactivity.
    J Biol Chem. 1994 Dec 23;269(51):32634-8 PMID: 7798269
  59. Expression of transforming growth factor-beta 1 in human bladder cancer.
    Cancer. 1995 May 15;75(10):2565-70 PMID: 7736402
  60. Secretion of transforming growth factor-beta 1 and -beta 2 by malignant glioma cells.
    Neurol Med Chir (Tokyo). 1995 Jul;35(7):423-30 PMID: 7477684
  61. Inhibition by tranilast of vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF)-induced increase in vascular permeability in rats.
    Life Sci. 1998;63(4):PL71-4 PMID: 9698042
  62. TGF-beta receptors: structure and function.
    Cell Mol Biol (Noisy-le-grand). 1994 May;40(3):337-49 PMID: 7920178
  63. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis.
    Genes Dev. 2000 Jan 15;14(2):163-76 PMID: 10652271
  64. N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits transforming growth factor-beta relesase and reduces migration and invasiveness of human malignant glioma cells.
    Int J Cancer. 2001 Jul 1;93(1):53-61 PMID: 11391621
  65. Activation of latent transforming growth factor beta.
    Adv Pharmacol. 1993;24:51-76 PMID: 8504067
  66. Regulation of antibody production and class switching by TGF-beta.
    J Immunol. 1995 Aug 15;155(4):1647-51 PMID: 7636223
  67. Anti-(transforming growth factor beta) antibodies with predefined specificity inhibit metastasis of highly tumorigenic human xenotransplants in nu/nu mice.
    Cancer Immunol Immunother. 1995 Nov;41(5):302-8 PMID: 8536276
  68. Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation.
    J Clin Oncol. 2001 Sep 1;19(17):3758-65 PMID: 11533099
  69. Role of transforming growth factor-beta1 in the suppressed allostimulatory function of AIDS patients.
    AIDS. 1998 Mar 26;12(5):481-7 PMID: 9543446
  70. Effect of the expression of transforming growth factor-beta 2 in primary human glioblastomas on immunosuppression and loss of immune surveillance.
    J Neurosurg. 1992 May;76(5):799-804 PMID: 1373442
  71. Thrombospondin binds and activates the small and large forms of latent transforming growth factor-beta in a chemically defined system.
    J Biol Chem. 1994 Oct 28;269(43):26775-82 PMID: 7929413
  72. Effects of anti-transforming growth factor-beta antibody and interleukin-2 in tumor-bearing mice.
    Cancer Biother. 1993 Summer;8(2):159-70 PMID: 7804355
  73. Transforming growth factor-beta in breast cancer: a working hypothesis.
    Breast Cancer Res Treat. 1997 Aug;45(1):81-95 PMID: 9285120
  74. Involvement of extracellular signal-regulated kinase 2 and stress-activated protein kinase/Jun N-terminal kinase activation by transforming growth factor beta in the negative growth control of breast cancer cells.
    Cancer Res. 1997 Feb 15;57(4):628-33 PMID: 9044838
  75. Inhibition of interferon-gamma and interleukin-2 production from lymphocytes stimulated with food antigens by an anti-allergic drug, Tranilast, in patients with food-sensitive atopic dermatitis.
    Biotherapy. 1994;8(1):19-22 PMID: 7547077
  76. TGF-beta signaling in tumor suppression and cancer progression.
    Nat Genet. 2001 Oct;29(2):117-29 PMID: 11586292
  77. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.
    J Clin Invest. 1993 Dec;92(6):2569-76 PMID: 7504687
  78. Negative regulation of transforming growth factor-beta by the proteoglycan decorin.
    Nature. 1990 Jul 19;346(6281):281-4 PMID: 2374594
  79. Transforming growth factor beta 1 is significantly elevated in plasma of patients suffering from renal cell carcinoma.
    Cytokine. 1996 Oct;8(10):794-8 PMID: 8980881
  80. Loss of receptors for transforming growth factor beta in human T-cell malignancies.
    Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):6002-6 PMID: 8016105
  81. In vitro growth inhibition of ovarian cancer cells by decorin: synergism of action between decorin and carboplatin.
    Cancer Res. 1999 Dec 15;59(24):6192-6 PMID: 10626812
  82. Excessive production of transforming growth-factor beta 1 can play an important role in the development of tumorigenesis by its action for angiogenesis: validity of neutralizing antibodies to block tumor growth.
    Biochim Biophys Acta. 1992 Oct 27;1137(2):189-96 PMID: 1384712
  83. Expression of transforming growth factor-beta 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression.
    Am J Pathol. 1994 Jul;145(1):97-104 PMID: 8030760
  84. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling.
    Nature. 1997 Oct 9;389(6651):631-5 PMID: 9335507
  85. The recombinant proregion of transforming growth factor beta1 (latency-associated peptide) inhibits active transforming growth factor beta1 in transgenic mice.
    Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5877-82 PMID: 8650186
  86. Generation of lymphokine-activated killer activity in T cells. Possible regulatory circuits.
    J Immunol. 1991 May 15;146(10):3280-8 PMID: 1673980
  87. Altered transforming growth factor signaling in epithelial cells when ras activation is blocked.
    J Biol Chem. 1996 Sep 13;271(37):22368-75 PMID: 8798398
  88. Cyclosporine induces cancer progression by a cell-autonomous mechanism.
    Nature. 1999 Feb 11;397(6719):530-4 PMID: 10028970
  89. Role of transforming growth factor beta in cancer.
    J Cell Physiol. 2001 Feb;186(2):153-68 PMID: 11169452
  90. Increase of plasma transforming growth factor beta (TGF beta) during immunotherapy with IL-2.
    Cancer Invest. 1995;13(6):583-9 PMID: 7583707
  91. Inhibitory effects of tranilast on expression of transforming growth factor-beta isoforms and receptors in injured arteries.
    Atherosclerosis. 1998 Apr;137(2):267-75 PMID: 9622270
  92. Analysis of the TGF beta functional pathway in epithelial ovarian carcinoma.
    Br J Cancer. 2001 Sep 1;85(5):687-91 PMID: 11531253
  93. Antiangiogenic and antitumor effects of tranilast on mouse lung carcinoma cells.
    Int J Oncol. 2000 Dec;17 (6):1151-6 PMID: 11078800
  94. Tranilast and cisplatin as an experimental combination therapy for scirrhous gastric cancer.
    Int J Oncol. 1998 Dec;13(6):1235-40 PMID: 9824637
  95. Abrogation of Smad3 and Smad2 or of Smad4 gene expression positively regulates murine embryonic lung branching morphogenesis in culture.
    Dev Biol. 1998 Feb 15;194(2):182-95 PMID: 9501027
  96. Transforming growth factor beta and fibroblast growth factor as promoters of tumor progression to malignancy.
    Crit Rev Oncog. 1993;4(5):473-92 PMID: 8241321
  97. Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor beta antibody and interleukin-2.
    J Immunother Emphasis Tumor Immunol. 1996 May;19(3):169-75 PMID: 8811491
  98. TGF-beta receptors and signalling mechanisms.
    Miner Electrolyte Metab. 1998;24(2-3):120-30 PMID: 9525694
  99. Tumor necrosis factor-alpha mediates the release of bioactive transforming growth factor-beta in murine microglial cell cultures.
    Clin Immunol Immunopathol. 1995 Dec;77(3):358-65 PMID: 7586747
  100. Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo.
    Cancer Res. 1997 Aug 1;57(15):3200-7 PMID: 9242450
  101. Signaling by chimeric erythropoietin-TGF-beta receptors: homodimerization of the cytoplasmic domain of the type I TGF-beta receptor and heterodimerization with the type II receptor are both required for intracellular signal transduction.
    EMBO J. 1996 Sep 2;15(17):4485-96 PMID: 8887540
  102. Immunohistochemical localization of transforming growth factor-beta 1 in Kaposi's sarcoma.
    Hum Pathol. 1995 May;26(5):469-73 PMID: 7750930
  103. Fetuin/alpha2-HS glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine antagonist.
    J Biol Chem. 1996 May 31;271(22):12755-61 PMID: 8662721
  104. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice.
    Science. 1992 Dec 11;258(5089):1795-8 PMID: 1465616
  105. Pleiotropic effects of transforming growth factor-beta on cells of the immune system.
    Ann N Y Acad Sci. 1993 Jun 23;685:488-500 PMID: 8363258
  106. Transforming growth factor-beta: expression in normal and pathological conditions.
    Horm Res. 1994;42(1-2):5-8 PMID: 7959634
  107. TGF-beta, radiation-induced pulmonary injury and lung cancer.
    Int J Radiat Biol. 2000 Apr;76(4):511-6 PMID: 10815631
  108. Transforming growth factor beta and the cell surface in tumor progression.
    Cancer Metastasis Rev. 1993 Sep;12(3-4):239-54 PMID: 8281611
  109. Inhibitory effect of tranilast on activation and transforming growth factor beta 1 expression in cultured rat stellate cells.
    Biochem Biophys Res Commun. 1996 Oct 14;227(2):322-7 PMID: 8878516
  110. The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms.
    Genes Dev. 1994 Jan;8(2):133-46 PMID: 8299934
  111. Inhibitory effects of transforming growth factor-beta (TGF-beta) on certain functions of intraepithelial lymphocytes.
    Clin Exp Immunol. 1999 Mar;115(3):415-20 PMID: 10193412
  112. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy.
    Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2909-14 PMID: 8610141
  113. TGF-beta: structure, function, and formation.
    Thromb Haemost. 1993 Jul 1;70(1):177-9 PMID: 8236098
  114. Type beta transforming growth factor in human platelets: release during platelet degranulation and action on vascular smooth muscle cells.
    J Cell Biol. 1986 Apr;102(4):1217-23 PMID: 3457014
  115. Decorin gene transfer-mediated suppression of TGF-beta synthesis abrogates experimental malignant glioma growth in vivo.
    Gene Ther. 1998 Sep;5(9):1187-94 PMID: 9930319
  116. Origin of plasma alpha2HS-glycoprotein and its accumulation in bone.
    Nature. 1976 Jul 15;262(5565):226-7 PMID: 934340
  117. Immunotherapy with low-dose interleukin-2 and anti-transforming growth factor-beta antibody in a murine tumor model.
    Cancer Biother. 1994 Winter;9(4):317-27 PMID: 7719379
Article Info
Journal
Investigational new drugs
Abbr.
Invest New Drugs
ISSN
0167-6997
DOI
10.1023/a:1022951824806
Email
[email protected]
Published
2003-02-00
Pages
21-32
Language
English
Region
United States
NLM ID
8309330
Subset
IM
External Links
PubMed source DOI: 10.1023/a:1022951824806 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2